|
 |
Ticari isim |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Mabthera |
Almanya, Arjantin, Avustralya, Avusturya, Belçika, Birleşik Arap Emirlikleri, Büyük Britanya, Danimarka, Ekvador, Fas, Finlandiya, Fransa, Hırvatistan, Hollanda, İrlanda, İspanya, İsveç, İsviçre, İtalya, İzlanda, Japonya, Kolombiya, Lüksemburg, Macaristan, Meksika, Mısır, Norveç, Peru, Polonya, Portekiz, Romanya, Şili, Suudi Arabistan, Tunus, Türkiye, Venezuela, Yeni Zelanda, Yunanistan |
|
Novex |
Arjantin |
|
Reditux |
Peru, Şili |
|
Rigetuxer |
Meksika |
|
Rituxan |
Amerika Birleşik Devletleri, Japonya, Kanada |
|
Rituximab |
Yeni Zelanda |
|
Rixathon |
Almanya, Belçika, Büyük Britanya, Fransa, İspanya, İsviçre |
|
Truxima |
Almanya, Amerika Birleşik Devletleri, Belçika, Büyük Britanya, Fransa, İspanya, Kanada |
|
|
 |
 |
Kaynaklar : Rituximab |
|
|
Tip |
Yayın |
| 2296 |
Laboratuar |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017 |
| 2825 |
Dergi |
Mueller C, Dietel E, Heynen S, Nalenz H, Goldbach P, Mahler H, Schmidt J, Grauschopf U, Schoenhammer K.
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials.
Int J Pharm Compound 2015 ; 19, 3: 261-267. |
| 2881 |
Afiş |
Jaccoulet E, Guirao S, Morand K, Astier A, Paul M.
Stabilité d'un anticorps monoclonal d'intérêt thérapeutique après reconstitution: le rituximab.
SFPO Congress 2009 |
| 3323 |
Dergi |
Paul M, Vieillard V, Jaccoulet E, Astier A.
Long-term stability of diluted solutions of the monoclonal antibody rituximab.
Int J Pharm 2012 ; 436, 1-2: 282-290. |
| 4016 |
Dergi |
Vieillard V, Paul M, Ibrahim T, Astier A.
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bag.
Ann Pharm Fr 2017 ; 75, 6: 420-435. |
| 4040 |
Dergi |
Lamanna W.C, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, Schiestl M.
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
J Oncol Pharm Practice 2017 ;25,2: 269-278 |
| 4676 |
Afiş |
Borišek R, Šmid I.
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days.
EAHP Congress Vienna 2022 |
| 4708 |
Dergi |
Borišek R, Mischo A, Šmid I.
Study of the Stability of Sandoz Rituximab Biosimilar Rixathon®/Riximyo® When Subjected for up to 21 Days to Ambient Storage.
Drugs R D 2022 ; 22,3: 225–234 |
| 4740 |
Laboratuar |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021
Roche Products Limited 2021 |
|
|
